539206 — Genomic Valley Biotech Income Statement
0.000.00%
- IN₹84.21m
- IN₹84.14m
- IN₹8.44m
Annual income statement for Genomic Valley Biotech, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | PRESS |
| Standards: | IAS | IAS | IAS | IAS | — |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 2.08 | 0.706 | 27.2 | 1.65 | 8.44 |
| Cost of Revenue | |||||
| Gross Profit | 1.26 | 0.686 | 11.4 | — | 6.43 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 5.32 | 1.08 | 21.2 | 1.51 | 4.07 |
| Operating Profit | -3.24 | -0.375 | 6.06 | 0.136 | 4.37 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -5.02 | -0.016 | 6.49 | 0.151 | 4.41 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -5.59 | -0.093 | 6.48 | 0.152 | 3.56 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -5.59 | -0.093 | 6.48 | 0.152 | 3.56 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -5.59 | -0.093 | 6.48 | 0.152 | 3.56 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.83 | -0.923 | 2.99 | 0.05 | 1.17 |
| Dividends per Share |